List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8586330/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
2	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 2003, 348, 2609-2617.	27.0	2,460
3	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
4	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	30.7	1,860
5	Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.	27.8	1,288
6	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 380, 1726-1737.	27.0	1,130
7	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	1.4	849
8	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116, 679-686.	1.4	790
9	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, The, 2021, 398, 314-324.	13.7	711
10	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	7.2	664
11	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 2012, 120, 2817-2825.	1.4	608
12	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. Journal of Clinical Oncology, 2006, 24, 3113-3120.	1.6	587
13	Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	27.0	460
14	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, 123, 1826-1832.	1.4	327
15	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 2013, 98, 1753-1761.	3.5	300
16	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	1.4	282
17	Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2012, 30, 1953-1959.	1.6	273
18	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 2017, 23, 3307-3315.	7.0	203

#	Article	IF	CITATIONS
19	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
20	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell, 2021, 39, 1028-1030.	16.8	176
21	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood, 2014, 123, 1461-1469.	1.4	174
22	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 2022, 387, 132-147.	27.0	173
23	Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of Clinical Oncology, 2023, 41, 1265-1274.	1.6	160
24	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4055-4061.	7.0	154
25	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	1.6	152
26	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
27	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Lancet Haematology,the, 2015, 2, e516-e527.	4.6	140
28	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 859-866.	1.6	140
29	Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood, 2016, 127, 2561-2568.	1.4	139
30	A phase 2 multicentre study of siltuximab, an antiâ€interleukinâ€6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2013, 161, 357-366.	2.5	138
31	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. Journal of Hematology and Oncology, 2020, 13, 94.	17.0	107
32	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 310-318.	0.4	104
33	A phase 1 study of lucatumumab, a fully human antiâ€ <scp>CD</scp> 40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2012, 159, 58-66.	2.5	101
34	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results Journal of Clinical Oncology, 2020, 38, 8503-8503.	1.6	93
35	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 2021, 27, 2099-2103.	30.7	92
36	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 812-818.	1.6	85

#	Article	IF	CITATIONS
37	Updated survival analyses after prolonged followâ€up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology, 2008, 143, 537-540.	2.5	84
38	State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. European Journal of Radiology, 2014, 83, 2203-2223.	2.6	78
39	Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). Blood, 2019, 134, 577-577.	1.4	78
40	First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results Journal of Clinical Oncology, 2017, 35, 3010-3010.	1.6	76
41	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 2022, 12, 32.	6.2	73
42	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 372-380.	0.4	66
43	Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma Journal of Clinical Oncology, 2020, 38, 8505-8505.	1.6	66
44	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 22-25.	1.4	63
45	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. Blood, 2020, 136, 25-26.	1.4	63
46	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 450-464.	7.0	62
47	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	16.8	62
48	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	7.2	54
49	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 29-34.	0.4	53
50	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10.	6.2	53
51	bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study Journal of Clinical Oncology, 2018, 36, 8007-8007.	1.6	50
52	Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. Blood, 2016, 128, 4486-4486.	1.4	49
53	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Science Advances, 2021, 7, eabg9551.	10.3	49
54	REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 41-42.	1.4	48

#	Article	IF	CITATIONS
55	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	5.0	46
56	Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. Blood, 2021, 138, 548-548.	1.4	45
57	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Frontiers in Immunology, 2018, 9, 2616.	4.8	44
58	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 116.	6.2	44
59	Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discovery, 2021, 2, 423-433.	5.0	43
60	BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity. Blood, 2012, 120, 4042-4042.	1.4	42
61	Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica, 2014, 99, e162-e164.	3.5	39
62	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances, 2017, 1, 1575-1583.	5.2	39
63	Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 549-549.	1.4	36
64	Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. Blood, 2013, 122, 532-532.	1.4	34
65	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 2018, 180, 821-830.	2.5	32
66	Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. Blood, 2020, 136, 26-27.	1.4	32
67	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Advances, 2018, 2, 1470-1479.	5.2	31
68	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 632-636.e1.	0.4	31
69	Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 3176-3176.	1.4	31
70	Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib. Blood, 2014, 124, 4736-4736.	1.4	31
71	Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2021, 138, 160-160.	1.4	31
72	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. British Journal of Haematology, 2018, 182, 495-503.	2.5	30

#	Article	IF	CITATIONS
73	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 305-305.	1.4	30
74	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 651-651.	1.4	30
75	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer, 2018, 124, 4342-4349.	4.1	29
76	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell, 2022, 40, 441-443.	16.8	29
77	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 555-562.	0.4	28
78	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 16-17.	1.4	28
79	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 480-485.e3.	0.4	27
80	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 326-335.	0.4	27
81	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 329-334.e1.	0.4	26
82	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research, 2016, 76, 1225-1236.	0.9	25
83	Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression. Blood, 2012, 120, 331-331.	1.4	24
84	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 351-357.	0.4	23
85	Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1 Journal of Clinical Oncology, 2021, 39, 8005-8005.	1.6	23
86	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood, 2019, 134, 3116-3116.	1.4	23
87	Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset. Blood, 2019, 134, 928-928.	1.4	23
88	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 140-140.	1.4	22
89	Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients. Blood, 2013, 122, 758-758.	1.4	21
90	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 2016, 128, 491-491.	1.4	21

#	Article	IF	CITATIONS
91	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precision Oncology, 2018, 2018, 1-17.	3.0	20
92	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp> . American Journal of Hematology, 2021, 96, E5-E8.	4.1	20
93	Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. Blood, 2010, 116, 3049-3049.	1.4	19
94	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). Blood, 2013, 122, 759-759.	1.4	19
95	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183 Journal of Clinical Oncology, 2018, 36, 8021-8021.	1.6	19
96	A phase lb study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results Journal of Clinical Oncology, 2020, 38, 8539-8539.	1.6	19
97	Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leukemia and Lymphoma, 2016, 57, 2510-2515.	1.3	18
98	SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 537-544.	0.4	18
99	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. Cancer, 2020, 126, 4332-4340.	4.1	18
100	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Blood, 2020, 136, 16-17.	1.4	18
101	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
102	Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220). Blood, 2019, 134, 3119-3119.	1.4	17
103	Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 272-276.	0.4	16
104	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Expert Review of Hematology, 2020, 13, 943-958.	2.2	16
105	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	4.1	16
106	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. Blood, 2012, 120, 202-202.	1.4	16
107	Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clinical Drug Investigation, 2022, 42, 29-41.	2.2	16
108	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 2022, 12, .	6.2	16

#	Article	IF	CITATIONS
109	Adverse drug reaction: pomalidomide-induced liver injury. Lancet, The, 2014, 383, 2125-2126.	13.7	15
110	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15
111	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	4.1	15
112	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematology,the, 2021, 8, e794-e807.	4.6	15
113	Connect MM Registry as a national reference for United States multiple myeloma patients. Cancer Medicine, 2020, 9, 35-42.	2.8	14
114	A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma. Blood, 2015, 126, 4226-4226.	1.4	14
115	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood, 2011, 118, 1876-1876.	1.4	13
116	Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. Blood, 2012, 120, 4061-4061.	1.4	13
117	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2014, 124, 302-302.	1.4	13
118	Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDEâ€1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem, 2022, 3, 97-108.	1.0	13
119	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e470-e476.	0.4	12
120	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	12
121	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). Blood, 2010, 116, 985-985.	1.4	12
122	Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2013, 122, 3220-3220.	1.4	12
123	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). Blood, 2014, 124, 4764-4764.	1.4	12
124	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study. Blood, 2016, 128, 194-194.	1.4	12
125	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety Journal of Clinical Oncology, 2013, 31, 8542-8542.	1.6	12
126	KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa Journal of Clinical Oncology, 2020, 38, 8525-8525.	1.6	12

#	Article	IF	CITATIONS
127	Digital Health for Patients With Multiple Myeloma: An Unmet Need. JCO Clinical Cancer Informatics, 2021, 5, 1096-1105.	2.1	12
128	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	17.0	11
129	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. Blood, 2012, 120, 450-450.	1.4	11
130	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. Blood, 2014, 124, 31-31.	1.4	11
131	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT) Journal of Clinical Oncology, 2012, 30, 8016-8016.	1.6	11
132	Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma. Journal of Clinical Pharmacology, 2017, 57, 663-677.	2.0	10
133	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Clinical Therapeutics, 2018, 40, 1193-1202.e1.	2.5	10
134	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Therapeutic Advances in Hematology, 2021, 12, 204062072098707.	2.5	10
135	Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up Journal of Clinical Oncology, 2013, 31, 8543-8543.	1.6	10
136	The effect of novel therapies in high-molecular-risk multiple myeloma. Clinical Advances in Hematology and Oncology, 2017, 15, 870-879.	0.3	10
137	Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e526-e531.	0.4	10
138	Where you live can impact your cancer risk: a look at multiple myeloma in New York City. Annals of Epidemiology, 2020, 48, 43-50.e4.	1.9	9
139	Phase 1b trial of isatuximab, an anti D38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer, 2021, 127, 1816-1826.	4.1	9
140	Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study. Blood, 2020, 136, 45-46.	1.4	9
141	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. Blood, 2014, 124, 3445-3445.	1.4	9
142	Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study. Blood, 2021, 138, 550-550.	1.4	9
143	Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 1658-1658.	1.4	9
144	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. Blood, 2021, 138, 162-162.	1.4	9

9

#	Article	IF	CITATIONS
145	Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI Journal of Clinical Oncology, 2022, 40, 8028-8028.	1.6	9
146	Overall survival with oral selinexor plus lowâ€dose dexamethasone versus realâ€world therapy in tripleâ€classâ€refractory multiple myeloma. EJHaem, 2021, 2, 48-55.	1.0	8
147	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Advances, 2021, 5, 367-376.	5.2	8
148	Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 41-42.	1.4	8
149	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 303-303.	1.4	8
150	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM) Journal of Clinical Oncology, 2019, 37, 8014-8014.	1.6	8
151	Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. Cancers, 2021, 13, 5996.	3.7	8
152	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. Blood, 2020, 136, 6-7.	1.4	8
153	Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. Clinical	0.4	8
154	Comphoma, Mycloma and Leukemia, 2022, 22, 690-701. Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 356-369.	0.4	7
155	Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Review of Hematology, 2016, 9, 91-105.	2.2	7
156	A phase <scp>II</scp> trial of <scp>TBL</scp> â€12 sea cucumber extract in patients with untreated asymptomatic myeloma. British Journal of Haematology, 2018, 180, 296-298.	2.5	7
157	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 2208-2215.	1.3	7
158	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Review of Hematology, 2021, 14, 31-45.	2.2	7
159	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	4.1	7
160	Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. Blood, 2014, 124, 303-303.	1.4	7
161	Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells Journal of Clinical Oncology, 2018, 36, 8024-8024.	1.6	7
162	Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis. Blood, 2021, 138, 3938-3938.	1.4	7

#	Article	IF	CITATIONS
163	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precision Oncology, 2022, , .	3.0	7
164	Asymptomatic Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S78-S86.	0.4	6
165	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 680-686.	0.4	6
166	Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 541-545.	0.4	6
167	Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM) Journal of Clinical Oncology, 2021, 39, 8045-8045.	1.6	6
168	Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Review of Hematology, 2021, 14, 697-706.	2.2	6
169	E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients. Blood, 2018, 132, 3216-3216.	1.4	6
170	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). Blood, 2010, 116, 1954-1954.	1.4	6
171	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. Blood, 2010, 116, 986-986.	1.4	6
172	Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood, 2011, 118, 631-631.	1.4	6
173	Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry. Blood, 2016, 128, 4489-4489.	1.4	6
174	Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US. Oncology and Therapy, 2021, 9, 659-669.	2.6	6
175	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. Blood, 2021, 138, 2704-2704.	1.4	6
176	Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. Blood, 2021, 138, 1739-1739.	1.4	6
177	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	1.4	6
178	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. Cancer Medicine, 2016, 5, 500-505.	2.8	5
179	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 693-702.	0.4	5
180	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e975-e984.	0.4	5

#	Article	IF	CITATIONS
181	Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood, 2019, 134, 1854-1854.	1.4	5
182	Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 13-15.	1.4	5
183	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). Blood, 2010, 116, 3031-3031.	1.4	5
184	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2010, 116, 3060-3060.	1.4	5
185	Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. Blood, 2010, 116, 862-862.	1.4	5
186	KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM) Journal of Clinical Oncology, 2016, 34, TPS8070-TPS8070.	1.6	5
187	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. Blood, 2012, 120, 4058-4058.	1.4	5
188	Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies. Blood, 2021, 138, 2812-2812.	1.4	5
189	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. Blood, 2021, 138, 326-326.	1.4	5
190	Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. BioDrugs, 2022, 36, 13-25.	4.6	5
191	Effect of initial treatment on healthâ€related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect [®] MM Registry. British Journal of Haematology, 2021, 193, 93-100.	2.5	4
192	Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma. Blood, 2018, 132, 59-59.	1.4	4
193	Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). Blood, 2010, 116, 1953-1953.	1.4	4
194	Final Results From the Bortezomib-nail`ve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood, 2011, 118, 813-813.	1.4	4
195	A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma. Blood, 2013, 122, 5392-5392.	1.4	4
196	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study. Blood, 2015, 126, 722-722.	1.4	4
197	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis Journal of Clinical Oncology, 2013, 31, 8532-8532.	1.6	4
198	KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM) Journal of Clinical Oncology, 2016, 34, TPS8069-TPS8069.	1.6	4

#	Article	IF	CITATIONS
199	Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. Blood, 2010, 116, 1938-1938.	1.4	4
200	Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001. Blood, 2020, 136, 8-9.	1.4	4
201	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients. Blood, 2021, 138, 730-730.	1.4	4
202	Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma. Blood, 2021, 138, 4964-4964.	1.4	4
203	Monoclonal Gammopathy May Be of Unpredictable Significance. JAMA Oncology, 2019, 5, 1302.	7.1	3
204	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study Journal of Clinical Oncology, 2021, 39, 8036-8036.	1.6	3
205	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. Blood, 2010, 116, 1952-1952.	1.4	3
206	A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. Blood, 2011, 118, 3971-3971.	1.4	3
207	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. Blood, 2013, 122, 3181-3181.	1.4	3
208	A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma. Blood, 2014, 124, 3486-3486.	1.4	3
209	MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins. Blood, 2016, 128, 3277-3277.	1.4	3
210	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 4520-4520.	1.4	3
211	A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma Journal of Clinical Oncology, 2015, 33, 8528-8528.	1.6	3
212	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry Journal of Clinical Oncology, 2017, 35, 8023-8023.	1.6	3
213	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	3
214	Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations. Blood, 2020, 136, 9-10.	1.4	3
215	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2959-2961.	1.3	2
216	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e115-e116.	0.4	2

#	Article	IF	CITATIONS
217	Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e118-e119.	0.4	2
218	Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. Annals of Hematology, 2020, 100, 3057-3060.	1.8	2
219	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e734-e751.	0.4	2
220	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e341-e344.	0.4	2
221	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma Journal of Clinical Oncology, 2021, 39, 8024-8024.	1.6	2
222	Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect® MM Registry. Blood, 2019, 134, 3129-3129.	1.4	2
223	Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (clg FISH) Enhances the Quantitative Detection of Chromosome Abnormalities In Plasma Cell Neoplasms Compared to Conventional FISH. Blood, 2010, 116, 1198-1198.	1.4	2
224	Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study. Blood, 2010, 116, 1936-1936.	1.4	2
225	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics Blood, 2010, 116, 3803-3803.	1.4	2
226	Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study. Blood, 2014, 124, 2119-2119.	1.4	2
227	Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib. Blood, 2015, 126, 3051-3051.	1.4	2
228	Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof. Blood, 2015, 126, 4195-4195.	1.4	2
229	A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma Journal of Clinical Oncology, 2012, 30, 8020-8020.	1.6	2
230	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. Blood, 2010, 116, 1942-1942.	1.4	2
231	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood, 2011, 118, 1875-1875.	1.4	2
232	A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma. Blood, 2019, 134, 3101-3101.	1.4	2
233	Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study Journal of Clinical Oncology, 2020, 38, e20522-e20522.	1.6	2
234	Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs). Blood, 2021, 138, 821-821.	1.4	2

#	Article	IF	CITATIONS
235	Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. Oncology and Therapy, 2022, 10, 411-420.	2.6	2
236	Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e75.	0.4	1
237	Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e117-e118.	0.4	1
238	Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 129-132.	0.4	1
239	Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. Blood, 2019, 134, 1779-1779.	1.4	1
240	A 28 Day Schedule for Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood, 2011, 118, 2949-2949.	1.4	1
241	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. Blood, 2012, 120, 4070-4070.	1.4	1
242	A Comparison of the Outcomes of Early Versus Delayed Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. Blood, 2015, 126, 1993-1993.	1.4	1
243	Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. Blood, 2016, 128, 3448-3448.	1.4	1
244	Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. Blood, 2016, 128, 802-802.	1.4	1
245	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial Journal of Clinical Oncology, 2013, 31, 8588-8588.	1.6	1
246	Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry Journal of Clinical Oncology, 2017, 35, 8040-8040.	1.6	1
247	Treatment patterns in multiple myeloma: Real-world experience of the triple-class exposed (TCE) patient Journal of Clinical Oncology, 2020, 38, e20543-e20543.	1.6	1
248	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. Blood, 2010, 116, 1966-1966.	1.4	1
249	A Phase II Trial of TBL 12 Sea Cucumber Extract In Patients Withuntreated Asymptomatic Myeloma. Blood, 2010, 116, 5042-5042.	1.4	1
250	Outcomes of Plasma Cell Disorder Patients with Abnormal Hepatitis B and C Screening Tests Prior to Autologous Stem Cell Harvest and Transplantation. Blood, 2011, 118, 4472-4472.	1.4	1
251	Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1 Journal of Clinical Oncology, 2012, 30, 8035-8035.	1.6	1
252	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. Blood, 2016, 128, 3285-3285.	1.4	1

#	Article	IF	CITATIONS
253	Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab Journal of Clinical Oncology, 2020, 38, e20540-e20540.	1.6	1
254	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 2021, 138, 1634-1634.	1.4	1
255	Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPEâ,,¢) for Multiple Myeloma (MM) Digital Solution in Patients with MM. Blood, 2020, 136, 3-4.	1.4	1
256	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. Blood, 2020, 136, 39-41.	1.4	1
257	Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m ² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m ² . American Journal of Hematology, 2020, 95, E51-E54.	4.1	0
258	Outcomes of Salvage Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma Patients Relapsed After An Initial ASCT and Refractory to Bortezomib and Immunomodulatory Agents. Blood, 2011, 118, 4484-4484.	1.4	0
259	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. Blood, 2011, 118, 1024-1024.	1.4	0
260	Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) Journal of Clinical Oncology, 2012, 30, 8011-8011.	1.6	0
261	Prognostic value of post-inductionÂPET/CTÂin untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) Journal of Clinical Oncology, 2012, 30, e21006-e21006.	1.6	0
262	Patients with Newly Diagnosed Multiple Myeloma and a Gain of the Long Arms of Chromosome 1 Have Inferior Outcomes, Including Early Onset Extramedullary Disease, Despite the Use of Novel Triplet Regimens. Blood, 2012, 120, 4996-4996.	1.4	0
263	Lack of a Response by Serum Free Light Chains Performed Early Post Stem Cell Transplantation in Patients with Multiple Myeloma Predicts Inferior Progression Free and Overall Survival Blood, 2012, 120, 3127-3127.	1.4	0
264	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	1.4	0
265	Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. Blood, 2013, 122, 1965-1965.	1.4	0
266	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). Blood, 2013, 122, 1854-1854.	1.4	0
267	An Integrative Network Approach for Genomic Discovery and Personalized Therapy in Relapsed Multiple Myeloma. Blood, 2014, 124, 3426-3426.	1.4	0
268	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. Blood, 2015, 126, 1851-1851.	1.4	0
269	Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs. Blood, 2015, 126, 3311-3311.	1.4	0
270	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	1.4	0

#	Article	IF	CITATIONS
271	Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. Blood, 2016, 128, 357-357.	1.4	0
272	Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. Blood, 2016, 128, 4450-4450.	1.4	0
273	Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry Journal of Clinical Oncology, 2017, 35, e19527-e19527.	1.6	0
274	Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells Journal of Clinical Oncology, 2018, 36, e15062-e15062.	1.6	0
275	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study. Blood, 2018, 132, 1991-1991.	1.4	0
276	MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1. Blood, 2018, 132, 4464-4464.	1.4	0
277	Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. Blood, 2018, 132, 3253-3253.	1.4	0
278	Racial and insurance disparities in multiple myeloma management in a referral center Journal of Clinical Oncology, 2019, 37, e18140-e18140.	1.6	0
279	Are two sites better than one?: Sites of care and quality of myeloma treatment Journal of Clinical Oncology, 2019, 37, e18159-e18159.	1.6	0
280	Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect® MM Registry. Blood, 2019, 134, 1843-1843.	1.4	0
281	Medical resource utilization among multiple myeloma (MM) patients who were triple-exposed to a proteasome inhibitor, an immunomodulatory agent, and daratumumab Journal of Clinical Oncology, 2020, 38, e20539-e20539.	1.6	0
282	Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma. Blood, 2021, 138, 1601-1601.	1.4	0
283	Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma. Blood, 2021, 138, 4961-4961.	1.4	0
284	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. Blood, 2021, 138, 4720-4720.	1.4	0
285	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. Blood. 2020. 136. 48-50.	1.4	0
286	28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma. Blood, 2020, 136, 13-13.	1.4	0